The Maker of Ozempic Is Trying to Block Compounded Versions of Its Drug
Drugmaker Novo Nordisk’s attempts to shut down compounded versions of its weight-loss and diabetes drug semaglutide (Ozempic/Wegovy) have reignited debates over patents, pricing, and access to GLP‑1 medications. Commenters weigh safety concerns about unregulated or compounded products against frustration with U.S. price gouging, limited insurance coverage, and persistent shortages, noting that many patients turn to compounders, foreign pharmacies, or grey markets to afford treatment. Broader themes include how well these drugs actually work, their potential public-health impact on obesity and addiction, and whether the current patent and insurance systems are aligned with long-term societal interests.
Compounded GLP‑1 Drugs: Role, Legality, and Safety
- Compounded drugs are described as custom formulations for allergies, unavailable doses, or alternative routes (e.g., liquids or flavored versions for animals).
- Concern: some compounders are effectively making unapproved “copycats” of patented drugs like semaglutide and tirzepatide, marketed as cheaper “generics” without FDA approval or full clinical testing.
- Veterinary and human anecdotes note that brand‑name formulations are the ones actually tested in trials; compounded versions may differ in efficacy and safety.
- FDA cannot “approve” compounded drugs; users debate trusting compounders versus sticking to branded injectors.
- Some compounding pharmacies allegedly crush branded pills (e.g., oral semaglutide) or import peptide powder from overseas; questions raised about purity, sterility, and patent infringement.
- Users debate whether current lawsuits and FDA warnings are primarily about safety or about protecting profits.
Access, Pricing, and Insurance Dynamics
- Branded Ozempic/Wegovy/Mounjaro can cost ~$1,000/month in the US; compounded versions are cited around ~$200–350/month.
- US prices are reported as far higher than in Canada/UK; some see this as deliberate price‑gouging, others as a byproduct of US policy and weak bargaining.
- Many insurers only cover GLP‑1s for diabetes, not weight loss, pushing non‑diabetics toward compounders or foreign sourcing.
- Commenters note employer‑driven plan design, churn between insurers, and unclear long‑term cost–benefit data as reasons for limited coverage.
Effectiveness, Side Effects, and Alternatives
- Multiple users report large weight losses and improved comorbidities (e.g., sleep apnea, exercise tolerance), saying GLP‑1s finally make constant hunger/cravings manageable.
- Others flag side effects and risks: testicular pain on finasteride, GI issues, possible nutrient deficits on very low intake, and unknown long‑term maintenance strategies.
- Debate on obesity: some argue “just diet and exercise” is unrealistic against powerful biological and environmental pressures; others emphasize discipline and nutrition strategies (e.g., keto, fiber).
- Exercise is praised for health and weight maintenance but described as an inefficient primary tool for large fat loss relative to calorie control.
Ethics, Patents, and Public Health
- Patents on semaglutide extend to ~2030; many see current enforcement and pricing as maximizing profit during monopoly years.
- Some argue these drugs have such profound potential for obesity and addiction that governments should force lower prices or broader licensing.
- Others accept patent rights but criticize using regulatory tools to suppress compounders while supply remains constrained.